Revolution Medicines’ pan-RAS inhibitor Rasonque opened commercially with steep early traction after FDA approval, with the company reporting $198 million in sales in just five weeks and treatment starts for more than 5,000 patients. The rapid uptake is driving investors to revisit near-term revenue expectations for a drug aimed at pancreatic cancer. Market-watchers are likely to focus on how quickly real-world prescribing expands beyond initial centers and how durable demand remains as payers and clinicians assess benefit across patient subsets. The early commercial read-through also increases the stakes for competing approaches targeting KRAS-pathway biology. Separate reporting highlights equity market sensitivity to launch outcomes, with stock reactions and analyst recalibrations pointing to Rasonque as a key near-term bellwether for next-generation precision oncology in pancreas.